Sei Investments Co. grew its position in Cambrex Co. (NYSE:CBM) by 3,120.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,155 shares of the biotechnology company’s stock after acquiring an additional 4,026 shares during the period. Sei Investments Co.’s holdings in Cambrex were worth $228,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Stifel Financial Corp increased its holdings in shares of Cambrex by 0.8% in the second quarter. Stifel Financial Corp now owns 4,580 shares of the biotechnology company’s stock valued at $275,000 after purchasing an additional 37 shares in the last quarter. Piedmont Investment Advisors LLC bought a new stake in Cambrex in the 2nd quarter valued at $421,000. Tributary Capital Management LLC lifted its position in Cambrex by 22.3% in the 3rd quarter. Tributary Capital Management LLC now owns 232,919 shares of the biotechnology company’s stock valued at $12,811,000 after acquiring an additional 42,428 shares in the last quarter. California Public Employees Retirement System lifted its position in Cambrex by 4.4% in the 2nd quarter. California Public Employees Retirement System now owns 73,500 shares of the biotechnology company’s stock valued at $4,392,000 after acquiring an additional 3,100 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its position in Cambrex by 5.4% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 93,817 shares of the biotechnology company’s stock valued at $5,606,000 after acquiring an additional 4,841 shares in the last quarter.

In other news, CEO Steven M. Klosk sold 4,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $54.96, for a total transaction of $219,840.00. Following the transaction, the chief executive officer now directly owns 87,328 shares in the company, valued at approximately $4,799,546.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.48% of the stock is owned by insiders.

Several brokerages have commented on CBM. ValuEngine raised shares of Cambrex from a “hold” rating to a “buy” rating in a research report on Tuesday, August 22nd. BidaskClub lowered shares of Cambrex from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Finally, Craig Hallum restated a “buy” rating and set a $60.00 price objective (down from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $62.33.

Cambrex Co. (NYSE:CBM) opened at $48.95 on Friday. The firm has a market cap of $1,635.60, a PE ratio of 15.74, a PEG ratio of 1.12 and a beta of 2.26. Cambrex Co. has a 52 week low of $42.55 and a 52 week high of $62.95.

Cambrex (NYSE:CBM) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.08. The company had revenue of $112.60 million for the quarter, compared to analyst estimates of $108.44 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. Cambrex’s revenue for the quarter was up 13.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.47 EPS. equities research analysts forecast that Cambrex Co. will post 2.97 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/cambrex-co-cbm-shares-bought-by-sei-investments-co/1765396.html.

Cambrex Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.